Boehringer Ingelheim inks deal for Sosei’s GPR52-targeting schizophrenia portfolio

Boehringer In­gel­heim is team­ing up with So­sei Hep­tares to ad­vance drug can­di­dates with the po­ten­tial to treat all three as­pects of schiz­o­phre­nia in a deal that in­cludes €25 mil­lion ($27.3 mil­lion) up­front.

Boehringer will get an ex­clu­sive op­tion to li­cense So­sei’s col­lec­tion of GPR52 ag­o­nists, in­clud­ing its first-in-class pro­gram, HTL0048149. So­sei could re­ceive a €60 mil­lion ($65.6 mil­lion) op­tion ex­er­cise pay­ment and up to €670 mil­lion ($732.9 mil­lion) in mile­stones plus tiered roy­al­ties, per a com­pa­ny re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.